Eckert & Ziegler SE Stock: price and directors' dealings · Germany · BaFin

About Eckert & Ziegler SE

Eckert & Ziegler SE is a European reference player in isotope technology, with a strong focus on medical, scientific, and industrial applications. Listed on Xetra/Frankfurt (DAX/MDAX/SDAX) in Germany, the company fits squarely within the healthcare universe, but with a distinctly technology-driven niche: it supplies critical inputs and specialized services across the radiopharmaceutical value chain. The group was founded in 1997 as a holding company, while its industrial roots go back further through legacy isotope research and technology activities in Germany. Its headquarters are in Berlin, and it operates an international network of subsidiaries and production sites serving customers in Europe, the United States, and other regions.\n\nThe business model is built around two main segments: Medical and Isotope Products. The Medical segment is focused on oncology and nuclear medicine, including products and services used in targeted radiation therapy, diagnostics, and theranostic applications. The Isotope Products segment serves industrial and scientific customers with radiation sources, isotope-based components, and radiometry solutions. This two-pronged structure gives the company diversification across end markets while benefiting from high regulatory barriers, GMP-compliant manufacturing capabilities, and deep expertise in handling radioactive materials.\n\nAmong the company’s best-known products is GalliaPharm®, a gallium-68 generator used in nuclear medicine imaging. Eckert & Ziegler also supplies lutetium-177, yttrium-90, and actinium-225, radionuclides that are increasingly important for next-generation targeted therapies. In recent periods, the company has strengthened its profile through partnership announcements with biotech and radiopharma names such as Bicycle Therapeutics, Pentixapharm, and Actinium Pharmaceuticals, reinforcing its role as a trusted manufacturing and supply partner for innovative cancer treatment developers.\n\nCompetitive positioning is supported by technical know-how, a global customer base, and a reputation for reliability in a market where quality, regulatory compliance, and supply continuity are essential. The company has also highlighted capacity expansion initiatives, particularly around actinium-225, one of the most strategically important isotopes for alpha therapy.\n\nRecent milestones include the 2024 conversion into an SE, the Pentixapharm spin-off, and continued commercial momentum in medical isotopes. For international investors, Eckert & Ziegler offers structural growth exposure tied to oncology innovation, but with meaningful sensitivity to regulatory execution, manufacturing scale-up, and the pace of radiopharmaceutical adoption.